Skip to main content
Clinical Trials/ChiCTR2100050648
ChiCTR2100050648Active, not recruitingEarly Phase 1

抗血小板药物对脓毒症的治疗效果与安全性研究

自筹1 site in 1 country61 target enrollmentStarted: September 15, 2021Last updated:

Trial Snapshot

Phase
Early Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
61
Locations
1
Primary Endpoint
降钙素原

Study Overview

Brief Summary

主要目的:探究抗血小板药物对脓毒症的治疗效果及安全性研究。

Study Design

Study Type
干预性研究
Primary Purpose
随机平行对照
Masking
None

Eligibility Criteria

Ages
18 to 80 (—)
Sex
All

Inclusion Criteria

  • 2.符合脓毒症诊断标准;
  • 3.入院前 6 个月未服用抗血小板药物;
  • 4.无严重恶性肿瘤,血液系统疾病或严重肝肾功能异常;
  • 5.血小板计数≧50×10^9。

Exclusion Criteria

  • 1.妊娠或哺乳期妇女;
  • 2.既往存在药物过敏史。

Arms & Interventions

试验组

常规治疗+阿司匹林

对照组

常规治疗

Outcomes

Primary Outcomes

降钙素原

白细胞计数

病死率

Time Frame: 治疗 28 天后

急性生理学与慢性健康状况评分Ⅱ

全身感染相关性器官功能衰竭评价

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
自筹

Study Sites (1)

Loading locations...

Similar Trials